¼¼°èÀÇ ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀå
Brucellosis Vaccines
»óǰÄÚµå : 1785892
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀåÀº 2030³â±îÁö 3¾ï 600¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 4,930¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 3.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 3¾ï 600¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ RB51 ¹é½ÅÀº CAGR 4.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 6,200¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. S19 ¹é½Å ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 3.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6,790¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀåÀº 2024³â¿¡´Â 6,790¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 6,130¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.3%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ºê·ç¼¿¶óº´ ¹é½ÅÀ̶õ ¹«¾ùÀ̸ç, ¿Ö ¼öÀÇÇÐ ¹× ÀÎü °Ç°­¿¡ Áß¿äÇѰ¡?

ºê·ç¼¿¶óº´ ¹é½ÅÀº °¡Ãà°ú °æ¿ì¿¡ µû¶ó¼­´Â »ç¶÷¿¡°Ôµµ ¿µÇâÀ» ¹ÌÄ¡´Â ºê·ç¼¿¶óº´ °¨¿°À» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ºê·ç¼¿¶ó±Õ¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â ºê·ç¼¿¶óº´Àº Àü¿°¼ºÀÌ ¸Å¿ì °­ÇÑ Àμö°øÅëÀü¿°º´À¸·Î °¡ÃàÀÇ ¹ø½ÄÀå¾Ö, ¹ß¿­, °üÀýÅë, ÇǷΰ¨ µî ½É°¢ÇÑ °Ç°­ ÇÕº´ÁõÀ» À¯¹ßÇÕ´Ï´Ù. ÀÌ Áúº´Àº ¼Ò, ¾ç, ¿°¼Ò, ¿°¼Ò, µÅÁö¿¡¼­ °¡Àå ¸¹ÀÌ ¹ß»ýÇϸç, Á÷Á¢ Á¢ÃË, ¿À¿°µÈ »ç·á, »ì±ÕµÇÁö ¾ÊÀº À¯Á¦Ç°À» ÅëÇØ °¨¿°µË´Ï´Ù. ¹é½Å Á¢Á¾Àº ¿©ÀüÈ÷ °¡Àå È¿°úÀûÀÎ ¿¹¹æ ¼ö´ÜÀ¸·Î Ãà»ê¾÷ÀÇ °æÁ¦Àû ¼Õ½ÇÀ» ÁÙÀ̰í ÀÎü °¨¿° À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¹é½ÅÀ¸·Î´Â S19, RB51(¼Ò¿ë), Rev-1(¾ç ¹× ¿°¼Ò¿ë) µîÀÌ ÀÖÀ¸¸ç, ¸ðµÎ ´ë±Ô¸ð ºê·ç¼¿¶óº´ÀÇ È®»êÀ» ¾ïÁ¦ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù À¯ÀüÀÚ ÀçÁ¶ÇÕ ¹é½Å, DNA ¹é½Å, º¤ÅÍ ±â¹Ý ¹é½ÅÀÇ ¹ßÀüÀ¸·Î ¸é¿ª¿ø¼º, ¾ÈÀü¼º, ¿¹¹æ È¿°ú°¡ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

ºê·ç¼¿¶óº´ ¹é½ÅÀÇ ÆÇµµ¸¦ ¹Ù²Ü ½Å±â¼úÀº?

»ý¸í°øÇаú ¸é¿ªÇÐÀÇ ¹ßÀü¿¡ µû¶ó ºê·ç¼¿¶óº´ ¹é½ÅÀÇ °³¹ßÀº ´«¿¡ ¶ç°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. S19³ª RB51°ú °°Àº ±âÁ¸ÀÇ ¾àµ¶È­ »ý¹é½ÅÀº È¿°úÀûÀ̱ä ÇÏÁö¸¸ º´¿ø¼ºÀÌ ³²¾ÆÀÖÀ» À§ÇèÀÌ ÀÖ°í, »ý¹°ÇÐÀû ¾ÈÀü¼º ¹®Á¦·Î ÀÎÇØ Á¢Á¾ÀÌ Á¦ÇѵǴ °æ¿ìµµ ÀÖ½À´Ï´Ù. Çö´ëÀÇ ¹é½Å Àü·«Àº º´¿ø¼º À§ÇèÀ» ÁÙÀ̸鼭 ¸é¿ª¿ø¼ºÀ» À¯ÁöÇÏ´Â À¯ÀüÀÚº¯Çü ¹é½Å¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¶ÇÇÑ »ì¾ÆÀÖ´Â ¹ÚÅ׸®¾Æ¸¦ µµÀÔÇÏÁö ¾Ê°í ƯÁ¤ ¹ÚÅ׸®¾Æ Ç׿øÀ» ÀÌ¿ëÇÏ¿© ¸é¿ªÀ» À¯µµÇÏ´Â ¾Æ´ÜÀ§ ¹é½ÅÀÇ ±â¼ú Çõ½Åµµ ¿¬±¸¸¦ ÅëÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³ª³ë º¸Á¶Á¦ ¹× ¸®Æ÷Á» Àü´Þ ½Ã½ºÅÛÀº ¹é½ÅÀÇ È¿´É°ú ¾ÈÁ¤¼ºÀ» ³ôÀÌ°í °¡ÃàÀÇ ¸é¿ª¹ÝÀÀÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. Àΰ£, µ¿¹°, ȯ°æÀÇ °Ç°­ Àü·«À» ÅëÇÕÇÏ´Â ¿øÇコ °³³äÀÇ ºÎ»óÀ¸·Î Àü¿°º´ÀÌ À¯ÇàÇÏ´Â Áö¿ª¿¡¼­ °¨½Ã¸¦ °­È­ÇÏ°í ¹é½ÅÀ» äÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¼¼°èµ¿¹°º¸°Ç±â±¸(WOAH), À¯¿£½Ä·®³ó¾÷±â±¸(FAO) µîÀÇ Á¤ºÎ ¹× ±â°üÀº ÀÌ Áúº´À» Àü ¼¼°è¿¡¼­ ±ÙÀýÇϱâ À§ÇØ Áý´Ü ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ ½Ç½Ã, Ç÷ûÇÐÀû ¸ð´ÏÅ͸µ, ¼öÀÇÇÐ ÀÎÇÁ¶ó °³¼±¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.

ºê·ç¼¿¶óº´ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â °¡Ãà »çÀ°µÎ¼ö Áõ°¡, Àμö°øÅëÀü¿°º´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áúº´ °ü¸®¿¡ ´ëÇÑ Á¤ºÎÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. µ¿¹°¿ë »ý¹°Á¦Á¦¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í »õ·Î¿î ¹é½Å Á¦Á¦ÀÇ ¿¬±¸°³¹ßÀÌ ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¾ÈÀüÇÑ Ãà»ê¹°¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ¼ö¿ä¿Í ³«³ó ¾ÈÀü ±ÔÁ¦°¡ ¹é½Å äÅà Áõ°¡¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±âÈÄ º¯È­¿Í ¼¼°è ¹«¿ªÀÇ È®´ë´Â ºê·ç¼¿¶óÁõ È®»ê¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, °¢±¹Àº ¿¹¹æ ¹é½Å Á¢Á¾ Àü·«ÀÇ ½ÇÇàÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù. µ¿¹°º´¿ø, Áø´Ü ½ÇÇè½Ç, °¡Ãà °ü¸® ÇÁ·Î±×·¥ÀÇ È®´ëµµ ½ÃÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¾ÆÇÁ¸®Ä« µî ºê·ç¼¿¶óº´ÀÌ ¿©ÀüÈ÷ À¯ÇàÇϰí ÀÖ´Â Áö¿ª¿¡¼­´Â Á¤ºÎ Áö¿ø ¹é½Å Á¢Á¾ ±¸»óÀÌ Ã·´Ü ¹é½Å¿¡ ´ëÇÑ ¼ö¿ä¸¦ °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, ¾÷°è´Â Å©°Ô ¼ºÀåÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(RB51 ¹é½Å, S19 ¹é½Å, B19 ¹é½Å, ±âŸ À¯Çü); ¿ëµµ(¼Ò¿ë, ¾ç¿ë, »ê¾ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Brucellosis Vaccines Market to Reach US$306.0 Million by 2030

The global market for Brucellosis Vaccines estimated at US$249.3 Million in the year 2024, is expected to reach US$306.0 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. RB51 Vaccine, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$162.0 Million by the end of the analysis period. Growth in the S19 Vaccine segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 6.6% CAGR

The Brucellosis Vaccines market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$61.3 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Brucellosis Vaccines Market - Key Trends & Drivers Summarized

What Are Brucellosis Vaccines and Why Are They Critical in Veterinary and Human Health?

Brucellosis vaccines are crucial in preventing Brucella infections, which affect livestock and, in some cases, humans. Brucellosis, caused by Brucella bacteria, is a highly contagious zoonotic disease that leads to reproductive failures in animals and severe health complications in humans, including fever, joint pain, and fatigue. The disease is most prevalent in cattle, sheep, goats, and pigs, with transmission occurring through direct contact, contaminated feed, or unpasteurized dairy products. Vaccination remains the most effective preventive measure, reducing economic losses in the livestock industry and minimizing the risk of human infection. The most commonly used vaccines include S19, RB51 (for cattle), and Rev-1 (for sheep and goats), all of which help in controlling the spread of brucellosis at a large scale. Recent advancements in recombinant vaccines, DNA vaccines, and vector-based vaccines have further enhanced immunogenicity, safety, and longevity of protection.

How Are Emerging Technologies Transforming the Brucellosis Vaccine Landscape?

With advancements in biotechnology and immunology, brucellosis vaccine development has evolved significantly. Traditional live-attenuated vaccines like S19 and RB51, though effective, carry risks of residual virulence and are restricted in certain cases due to biosafety concerns. Modern vaccine strategies now focus on genetically modified vaccines that retain immunogenicity while reducing risks of pathogenicity. Research is also driving innovation in subunit vaccines, which use specific bacterial antigens to trigger immunity without introducing live bacteria. Furthermore, nano-adjuvants and liposomal delivery systems are enhancing vaccine efficacy and stability, improving immune response in livestock. The rise of One Health initiatives-which integrate human, animal, and environmental health strategies-has led to increased surveillance and adoption of vaccines in endemic regions. Governments and organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) are working to implement mass vaccination programs, serological monitoring, and improved veterinary infrastructure to eradicate the disease globally.

The Growth in the Brucellosis Vaccines Market Is Driven by Several Factors…

Key growth drivers include rising livestock population, increasing awareness about zoonotic diseases, and stringent government regulations on disease control. Growing investments in veterinary biologics and R&D for novel vaccine formulations have further fueled market expansion. The global demand for safe livestock products and dairy safety regulations has led to an uptick in vaccine adoption. Additionally, climate change and global trade expansion are influencing the spread of brucellosis, prompting nations to implement preventive vaccination strategies. The expansion of veterinary clinics, diagnostic laboratories, and livestock management programs is also bolstering the market. In regions such as Asia-Pacific and Africa, where brucellosis remains endemic, government-backed vaccination initiatives are accelerating the demand for advanced vaccines, making the industry poised for significant growth.

SCOPE OF STUDY:

The report analyzes the Brucellosis Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine, Other Types); Application (Cattle Application, Sheep Application, Goat Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â